SCHEMBL1048920

SCHEMBL1048920

NC(=O)c1ccc(-c2cnc(Nc3ccccc3)c3c(=O)[nH]ccc23)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.53
ROCK2 O75116 1/20 0.53
MAP4K4 O95819 1/20 0.53
PIM1 P11309 1/20 0.53
PRKACA P17612 1/20 0.53
CDK2 P24941 1/20 0.53
GSK3B P49841 1/20 0.53
HIPK2 Q9H2X6 1/20 0.53
CLK4 Q9HAZ1 1/20 0.53
IRAK4 Q9NWZ3 1/20 0.53
IKBKB O14920 1/20 0.47
CHUK O15111 1/20 0.47
ZAP70 P43403 2/20 0.46
AURKB Q96GD4 3/20 0.44
EGFR P00533 2/20 0.44
INCENP Q9NQS7 1/20 0.44
TTBK1 Q5TCY1 2/20 0.44
TTBK2 Q6IQ55 2/20 0.44
AURKA O14965 1/20 0.43
JAK2 O60674 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1048999 0.88 ZAP70 (0.49) CDC7ROCK2MAP4K4PIM1PRKACA
SCHEMBL1049635 0.88 ZAP70 (0.53) CDC7ROCK2MAP4K4PIM1PRKACA
SCHEMBL1045599 0.85 ZAP70 (0.47) CDC7ROCK2MAP4K4PIM1PRKACA
SCHEMBL1048942 0.84 ZAP70 (0.48) ZAP70TTBK1TTBK2JAK2ALDH1A1
SCHEMBL1043299 0.84 JAK2 (0.49) GSK3BZAP70TTBK1TTBK2JAK2
SCHEMBL1049280 0.82 MAPT (0.49) GSK3BZAP70TTBK1TTBK2ALDH1A1
SCHEMBL1047746 0.82 ZAP70 (0.46) GSK3BZAP70AURKBTTBK1TTBK2
SCHEMBL1049397 0.81 NUDT1 (0.48) MAP4K4PRKACAGSK3BCLK4IKBKB
SCHEMBL1048512 0.81 ZAP70 (0.47) ZAP70AURKBEGFRINCENPTTBK1
SCHEMBL27806170 0.80 ZAP70 (0.51) CDC7ROCK2MAP4K4PIM1PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US claimed
CN-101990539-A Compounds and compositions as kinase inhibitors IRM LLC 2011-03-23 CN claimed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US claimed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP claimed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO claimed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP disclosed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FYN, SYK, RET CDC7 429/4885ROCK2 200/4885MAP4K4 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.